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EDITORIAL

Myriocin as an atherosclerosis inhibitor
‘It appears quite possible that
detailed investigations of the
antiatherogenic actions of
myriocin will reveal therapeutic
targets that can be more
selectively regulated in the future.’
Targeting the sphingolipid pathway to
treat atherosclerosis
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Atherosclerosis is a major cause of cardiovascular
disease and accounts for approximately 50% of all
deaths in westernized countries [1]. Atherosclerosis
develops as a consequence of multiple pathways
that involve dysregulated cellular proliferation,
lipid accumulation and inflammation [2,3]. Hypercholesterolemia is a major risk factor for atherosclerosis and it is clear that HMG-CoA reductase
inhibitors (statins) effectively lower serum total
and LDL-cholesterol (LDL-C), and reduce
cardiovascular morbidity and mortality [4]. However, it is well known that a significant number of
patients are either resistant to or intolerant to statins and, with recent guidelines for LDL-C levels
to be reduced below 2 mM, it has been reported
that fewer than 50% of patients treated with statins achieve their targets [5]. In order to address
this problem, statin combination therapies are
under investigation, for example, using the cholesterol-absorption inhibitor ezetimibe [5]. As an
adjunct to statin therapy, strategies targeting
proatherogenic pathways that are not primarily
aimed at reducing cholesterol synthesis or absorption would be predicted to result in a twopronged approach to treat atherosclerosis. As a
case in point, therapeutic targeting of the sphingolipid biosynthetic pathway may represent a
feasible approach to treat atherosclerosis [6,7].

exerts its potent antiatherogenic action is presently unknown. It is possible that myriocin may
exert its effects by modulation of several lipids
downstream of ceramide (such as glycosphingolipids [GSLs] and the bioactive lipids ceramide-1phosphate [C1P] and sphingosine-1-phosphate
[S1P]) and/or by altering the expression of antiatherogenic genes in the liver; and recent data
indicate that Apoa1 is one hepatic target [8,12].
We have previously emphasised the need to
focus on selective inhibition of specific branches
in the sphingolipid pathway in order to gain
mechanistic insights into the most valuable
therapeutic targets [7]. We demonstrated that
atherosclerosis in Apoe-/- mice is associated with
increased plasma and lesion concentrations of
GSLs [13]. More recently, we showed that the
antiatherogenic activity of myriocin was associated with significant reductions in plasma GSL
levels [8,9]. This led us to evaluate a selective
GSL-synthesis inhibitor D-threo-1-ethylendioxyphenyl-2-palmitoylamino-3-pyrrolidino-propanol (EtDO-P4) as a potential inhibitor of
atherosclerosis in Apoe-/- mice. The data from
this experiment indicated that 4 months of
EtDO-P4 administration to Apoe-/- mice (maintained on a high-fat diet) resulted in a 49%
reduction (p < 0.0001) in plasma GSL levels
compared with vehicle-treated mice, but this was
not associated with a significant reduction in
atherosclerosis [Glaros EN, Kim WS, Rye KA, Shayman JA,
Garner B, Unpublished Data]. This implies that the antiatherogenic action of myriocin is also not likely
to be based on reductions in GSL synthesis.
‘…myriocin may exert its effects by
modulation of several lipids downstream
of ceramide … and/or by altering the
expression of antiatherogenic
genes in the liver.’

Glycosphingolipids & atherosclerosis

part of

Work from my own group [8,9] and two independent groups [10,11] has shown that the serine
palmitoyl transferase (SPT) inhibitor myriocin is
a potent inhibitor of atherosclerosis in Apoe-/mice. Myriocin inhibits the initial step in the
sphingolipid biosynthetic pathway (Figure 1), so
the precise mechanism(s) by which myriocin
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Ceramide-1-phosphate
& atherosclerosis

Myriocin could potentially regulate the synthesis
of additional sphingolipids such as C1P. C1P is
generated by ceramide phosphorylation
catalyzed by ceramide kinase (Figure 1). It is
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established that C1P is a potent activator of
cytosolic phospholipase A2α and, thus, a key regulator of macrophage cytokine-induced eicosanoid metabolism [14–18]. Macrophage foam
cells present in atherosclerotic lesions secrete
proinflammatory molecules that accelerate disease progression [2]. The products of macrophage
eicosanoid metabolism, which include prostaglandins, leukotrienes and platelet-activating factors, are particularly important proinflammatory
mediators (Figure 1). Identification of the major
upstream regulators of macrophage eicosanoid
metabolism and the design of drugs that inhibit
such pathways is already recognized as a new
avenue to treat atherosclerosis [19]. It remains
possible that reductions in C1P generation
achieved by myriocin could result in anti-inflammatory actions that inhibit the development of
atherosclerosis in Apoe-/- mice. However, direct
evidence for this has so far not been provided.

potently suppressed atherosclerosis in both the
Apoe-/- and Ldlr-/- mouse models [20,21]; however,
the third study indicated that atherosclerosis was
not inhibited in Apoe-/- mice treated with
FTY720 and (in contrast to the other two studies) a marked hypercholesterolemia was reported
in the drug-treated animals [22]. The reasons for
this discrepancy are unclear, but it is worth noting that lesion data were reported only for the
aortic root in the latter study and this site has
been shown to be refractory to treatment in
other work [9].
‘It remains possible that reductions in
C1P generation achieved by myriocin
could result in anti-inflammatory actions
that inhibit the development of
atherosclerosis in Apoe-/- mice.’

It is thought that FTY720 is phosphorylated
in vivo and exerts most of its antiatherogenic
effects via interaction with S1P receptors (most
likely S1P1 and S1P3), which results in an antiinflammatory action [23]. At present, it is not
clear how FTY720 inhibited lesion development
in the two positive mouse studies. There were no
consistent changes in either macrophage or
CD3+ lymphocyte levels in lesions when the two
studies were compared. Paradoxically, the potent

Sphingosine-1-phosphate
& atherosclerosis

In contrast to C1P, which has not been studied
in vivo as a therapeutic target for atherosclerosis,
several studies have focused on the potential for
the S1P analogue FTY720 to modulate atherosclerosis in both Apoe-/- and Ldlr-/- mice [20–23].
Two of the studies reported that FTY720

Figure 1. Sphingolipid pathway and inhibitor targets.
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C1P: Ceramide-1-phosphate; CERK: Ceramide kinase; cPLA2: Phospholipase A2; GCT: Glucosylceramide
transferase; LacCer: Lactosylceramide; LysoPC: Lysophosphatidylcholine; PAF: Platelet-activating factor;
PC: Phosphatidylcholine; S1P: Sphingosine-1-phosphate; SPHK: Sphingosine kinase; SPT: Serine
palmitoyl transferase.
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antiatherogenic action of myriocin is associated
with decreased plasma levels of S1P in the order
of 73–81% [11].
Although one interpretation of these data could
be that the antiatherogenic effect of myriocin
could not be related to S1P production, our
recent studies indicating that the liver is an important site of myriocin action [8] imply that there
may be beneficial responses resulting from the
reduced hepatic S1P levels that are predicted to
result from myriocin treatment. It is well known
that sphingolipids are important mediators of
intracellular signaling pathways [24–26], and we are
currently investigating hepatic signaling pathways
that could potentially link the antiatherogenic
action of myriocin with S1P and C1P.
Myriocin as a new therapeutic for the
treatment of atheroslcerosis?

At present, it appears unlikely that myriocin will
be useful clinically. There are several reasons for
this. As already noted, myriocin inhibits SPT,
which blocks the first step in sphingolipid synthesis, and this is likely to impact on many members of the sphingolipid family that have
important roles in signaling and regulation of
cell growth, differentiation, apoptosis and
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‘At present, it appears unlikely that
myriocin will be useful clinically.’

Myriocin has, however, provided an important tool that has allowed us to begin to investigate which specific members of the sphingolipid
family may be selectively targeted to treat atherosclerosis. It appears quite possible that detailed
investigations of the antiatherogenic actions of
myriocin will reveal therapeutic targets that can
be more selectively regulated in the future.
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